SONN - Why Sonnet BioTherapeutics Stock (SONN) Is Getting Obliterated | Benzinga
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 24% to $0.21 Thursay afternoon after the company announced a 1-for-22 reverse stock split.
The company says the reverse stock split is intended to increase ...
SONN) Is Getting Obliterated>Full story available on Benzinga.com